Radiopharm Theranostics (ASX:RAD has received a payment of US$2.0 million from Nasdaq-listed Lantheus Holdings
The company said the payment is under the preclinical assets transfer and development agreement
announced on 20 June 2024.
It forms part of Lantheus' total investment package in Radiopharm. The package includes an initial investment of US$4.99 million, and a potential further investment of up to US$5 million) via options with a six-month term and the recent payment of US$2.0 million.
Radiopharm CEO and managing director Riccardo Canevari said, “I am delighted with the confidence demonstrated by Lantheus in settling the transfer and development agreement and making this payment ahead of the shareholder meeting later this month. We are well advanced in our strategic planning with Lantheus and the collaboration between our two companies augers well for the future."